公开(公告)号：US07569675B2

公开(公告)日：2009-08-04

申请号：US10242092

申请日：2002-09-11

Applicant: Haiying Xia ,  Zhida Huang

Inventor： Haiying Xia ,  Zhida Huang

IPC: C07K16/28 ,  C12P21/08 ,  G01N33/53 ,  G01N33/531 ,  G01N33/554 ,  G01N33/567 ,  G01N33/577 ,  C12N5/12 ,  G01N33/574

CPC classification number: C07K16/2869 ,  Y10S435/96 ,  Y10S436/813

Abstract: A lagomorph derived monoclonal antibody for recognizing the progesterone receptor (PR) (clone SP2) with immunohistochemistry and methods for creating such an antibody are disclosed. No need of target retrieval in immunohistochemistry is their prominent advantage compared to currently available PR antibody. Furthermore, the very low background when the lagomorph derived monoclonal antibody is used in immunohistochemistry is also impressive. The immunohistochemistry comparative study with about fifty clinical specimens showed that the new PR antibody (clone SP2) antibody had favorable results when compared to mouse monoclonal antibody PR (clone 1A6), the best one in the current market. The PR antibody may prove of great value in the assessment of PR status in human breast cancer. Humanized versions of the PR antibody may provide therapeutic benefits.

Abstract translation: 公开了使用免疫组织化学识别孕酮受体（PR）（克隆SP2）的抗兔衍生单克隆抗体及其产生方法。 与目前可获得的PR抗体相比，免疫组化中无需靶标检测是其突出优点。 此外，当使用来自拉莫美辛的单克隆抗体用于免疫组织化学时，非常低的背景也令人印象深刻。 与约50个临床标本的免疫组织化学比较研究显示，与目前市场上最好的小鼠单克隆抗体PR（克隆1A6）相比，新的PR抗体（克隆SP2）抗体具有有利的结果。 PR抗体可能在人乳腺癌PR状态评估中具有重要价值。 PR抗体的人源化版本可以提供治疗益处。

公开(公告)号：US11002738B2

公开(公告)日：2021-05-11

申请号：US15920367

申请日：2018-03-13

Applicant: Spring BioScience Corporation

Inventor： Yifei Zhu ,  Zhiming Liao ,  Fernando Jose Rebelo do Couto

IPC: G01N33/574 ,  C07K16/30 ,  C07K16/28 ,  G01N33/68

Abstract: The present application discloses anti-GPNMB antibodies and methods of using the same. The antibodies are selected to bind to an epitope located in a C-terminal fragment of the protein and are selected for specificity in immunohistochemical assays. The antibodies are useful in, for example, immunohistochemical methods of detecting GPNMB-positive cells in tumors.

公开(公告)号：US10436785B2

公开(公告)日：2019-10-08

申请号：US15363832

申请日：2016-11-29

Applicant: Spring BioScience Corporation

Inventor： Fernando Jose Rebelo do Couto ,  Zhiming Liao ,  Yifei Zhu

IPC: G01N33/573 ,  C07K16/40 ,  C12N9/02 ,  C12N9/96 ,  G01N33/574

Abstract: The invention provides antibodies that bind specifically to human indoleamine 2,3-dioxygenase 1 (IDO1), and methods of using the same. The antibodies are capable of binding to a sequence comprising SEQ ID NO: 1 and specifically bind to human IDO1 in formalin fixed paraffin embedded tissues. The antibodies are useful in a number of different analytical techniques, including immunohistochemistry (IHC) and immunocytochemistry (ICC).

公开(公告)号：US10689445B2

公开(公告)日：2020-06-23

申请号：US15727388

申请日：2017-10-06

Applicant: Ventana Medical Systems, Inc. ,  Spring BioScience Corporation

Inventor： Marcin Kowanetz ,  Hartmut Koeppen ,  Zachary Boyd ,  Zhiming Liao ,  Yifei Zhu ,  Bharathi Vennapusa ,  Patrick C. Roche

IPC: C07K16/28 ,  G01N33/53 ,  G01N33/574 ,  A61K39/395 ,  A61K45/06 ,  C07K14/705 ,  A61N5/10

Abstract: The invention provides programmed death-ligand 1 (PD-L1) antibodies and methods of using the same.

公开(公告)号：US09885721B2

公开(公告)日：2018-02-06

申请号：US14725953

申请日：2015-05-29

Applicant: Spring BioScience Corporation

Inventor： Fernando Jose Rebelo do Couto ,  Zhiming Liao ,  Yifei Zhu

IPC: C07K16/28 ,  C07K16/30 ,  G01N33/574

CPC classification number: G01N33/57492 ,  C07K16/2827 ,  C07K16/2896 ,  C07K2317/34 ,  C07K2317/51 ,  C07K2317/515 ,  C07K2317/92 ,  G01N2333/70596

Abstract: Provided herein are PD-L1 antibodies and methods for using the same for diagnosing a medical condition associated with elevated PD-L1 levels (e.g., cancer) in subjects in need thereof and antigen binding fragments thereof. The PD-L1 antibodies and antigen binding fragments are also useful in evaluating the efficacy of a particular therapeutic regime in a subject diagnosed as having a PD-L1-related medical condition.